About Amgen Inc.
Large-cap biotech selling blockbusters in osteoporosis (Prolia), cardiology (Repatha), and oncology, with MariTide as a high-stakes obesity pipeline catalyst. Yields ~2.8% with 13+ years of dividend growth. Very low beta (~0.47) provides defensive positioning, but binary trial readouts—especially obesity data—can move shares 10%+ overnight.
Biotechnology